GSK’s Bepirovirsen Receives the US FDA’s Fast Track Designation for the Treatment of Hepatitis B
Shots:
- The FTD was granted based on the results from the P-IIb trials incl. (B-Clear) evaluating the safety, efficacy & durability of Bepirovirsen vs PBO in patients (n=440) with chronic HBV infection randomized as those on stable NA (Cohort 1)/ or not (Cohort 2) & (B-Sure) follow-up study evaluating patients achieving a complete or partial response in the (B-Clear) study
- In both trials, patients depicted a clinically meaningful response with Bepirovirsen + oral NAs & the (B-Clear) trial showed the potential of patients with low baseline Hepatitis B surface antigen levels to benefit from bepirovirsen treatment
- Bepirovirsen, an antisense oligonucleotide (ASO), is currently being evaluated in a confirmatory P-III (B-Well) trial
Ref: GSK | Image: GSK
Related News:- GSK Reports the P-III Results for Blenrep (belantamab mafodotin) in Combiantion with BorDex (dexamethasone) to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
